Shionogi will receive $375 million to develop a long-acting protease inhibitor designed to prevent SARS-CoV-2 infection in people who are immune compromised.
BARDA to fund development of COVID preventive drug
Published in COVID-19
More from COVID-19More posts in COVID-19 »
- Report: COVID survivors nearly twice as likely to have ongoing symptoms as those with flu
- Imaging shows significant lung injury in kids with long COVID
- New data: Early fears that COVID raises risk of sudden cardiac events in athletes unfounded
- Vaccinated kids at 57% to 73% lower risk of long COVID, CDC study suggests